PHAXIAM Therapeutics (PHXM) F-3Shelf registration (foreign)

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

The Board of Directors

ERYTECH Pharma S.A.

We consent to the incorporation by reference in this registration statement on Form F-3 of ERYTECH Pharma S.A. of our report dated March 17, 2020, with respect to the consolidated statements of financial position of ERYTECH Pharma S.A. and its subsidiary as of December 31, 2019, 2018 and 2017, and the related consolidated statements of income (loss), comprehensive income (loss), changes in shareholders’ equity, and cash flows for each of the years in the three-year period ended December 31, 2019, and the related notes, which report appears in the Annual Report on Form 20-F of ERYTECH Pharma S.A for the year ended December 31, 2019 filed with the US. Securities and Exchange Commission on March 18, 2020, and to the references to our firm under the headings “Experts” in this registration statement.

Our report dated March 17, 2020 refers to the change in ERYTECH Pharma S.A.’s method of accounting for leases on January 1, 2019, due to the adoption of IFRS 16 “Leases”.

Lyon, September 21, 2020

KPMG Audit

Department of KPMG S.A.

/s/ Stéphane Devin

Stéphane Devin

Partner